Our platform assists pharmaceutical companies in their drug development pipeline by providing robust and highly specific drug response predictions from a broad group of patients.
new drug development
Our platform includes a fully profiled and replenishable model for major depression - allowing a rapid high-throughput identification of novel drugs and their molecular effects on cells.
IDENTIFYING CLINICAL TRIAL CANDIDATES
Our platform allows an invaluable identification of patients subsets for clinical trials, obviating the need for larger clinical trials and increasing the potential for successful outcomes.
Drugs that have already been approved by the regulatory agencies can be repurposed to treat depression, given the appropriate effects. Our platform can aid in identifying these effects rapidly and reliably.